These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 36077772)

  • 21. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
    Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tumor-stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma.
    Lu M; Zou Y; Fu P; Li Y; Wang P; Li G; Luo S; Chen Y; Guan G; Zhang S; Chen L
    Discov Oncol; 2023 Jul; 14(1):124. PubMed ID: 37405518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer.
    Group Young Researchers In Inflammatory Carcinogenesis ; Wandmacher AM; Mehdorn AS; Sebens S
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
    Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
    EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
    Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
    Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia.
    Opitz FV; Haeberle L; Daum A; Esposito I
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target.
    Wu C; Liu Y; Wei D; Tao L; Yuan L; Jing T; Wang B
    Front Oncol; 2022; 12():840474. PubMed ID: 35719923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.
    Muller M; Haghnejad V; Schaefer M; Gauchotte G; Caron B; Peyrin-Biroulet L; Bronowicki JP; Neuzillet C; Lopez A
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
    Mehra S; Deshpande N; Nagathihalli N
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FES null mice demonstrate a reduction in neutrophil dependent pancreatic cancer metastatic burden.
    Strøbech JE; Giuriatti P; Stagaard R; De Sepulveda P; Nielsen SR; Erler JT
    Front Oncol; 2023; 13():1096499. PubMed ID: 36969004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages.
    Li MX; Wang HY; Yuan CH; Ma ZL; Jiang B; Li L; Zhang L; Xiu DR
    Clin Sci (Lond); 2021 Feb; 135(4):629-649. PubMed ID: 33538300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.